Background GLP-1 receptor agonists (GLP-1 RAs) with exenatide bid first approved to treat
type 2 diabetes in 2005 have been further developed to yield effective compounds …

Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) remain as one
of the most global problematic metabolic diseases with rapidly increasing prevalence and …

Abstract Type 2 diabetes (T2D) is a widely prevalent disease with substantial economic and
social impact for which multiple conventional and novel pharmacotherapies are currently …

The management of type 2 diabetes mellitus (T2DM) is becoming increasingly complex.
Sodium–glucose cotransporter type 2 inhibitors (SGLT2is) are the newest antidiabetic …

Aims: Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2
inhibitors play a key role in the treatment of type 2 diabetes mellitus. This meta-analysis aims …

Abstract Type 2 diabetes (T2D) is a disease characterized by heterogeneously progressive
loss of islet β cell insulin secretion usually occurring after the presence of insulin resistance …

Background: Newer diabetes medications may have beneficial effects on mortality,
cardiovascular outcomes, and renal outcomes. Purpose: To evaluate the effectiveness …

The impressive results of recent clinical trials with glucagon-like peptide-1 receptor agonists
(GLP-1Ra) and sodium glucose transporter 2 inhibitors (SGLT-2i) in terms of cardiovascular …

BACKGROUND The pathophysiology of type 2 diabetes differs markedly by ethnicity.
PURPOSE A systematic review and meta-analysis was conducted to assess the impact of …

Background A network meta-analysis of randomized controlled trials (RCTs) was conducted
to explore the cardiovascular outcomes of all the kind and dosages of sodium-glucose …